Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Dr. Reddy’s Laboratories (RDY - Snapshot Report) recently launched its generic version of Pfizer’s (PFE - Analyst Report) pulmonary arterial hypertension (PAH) drug, Revatio (sildenafil) tablets. We note that Dr. Reddy’s is not the only company to launch a generic version of Revatio. Earlier this month, Mylan (MYL - Analyst Report) had launched its generic version of the drug.

Apart from Mylan and Dr. Reddy’s, Watson Pharmaceuticals also gained approval for its generic version of Revatio. Watson Pharma intends to launch its product shortly.

According to IMS Health, US sales of Revatio tablets in the 12 months ending September 30, 2012, were $338.7 million. While Revatio tablets lost exclusivity in September 2012, Revatio intravenous injection is slated to lose exclusivity in May 2013.

During the second quarter of fiscal 2013, Dr. Reddy’s launched 4 new generic products and filed 4 abbreviated new drug applications (ANDAs) with the US Food and Drug Administration (FDA).

Dr. Reddy’s generics division delivered a strong performance in North America (47%) in the second quarter of fiscal 2013. Generics revenues were driven by limited competition for the company’s generic versions of Pfizer’s Geodon (ziprasidone), Astellas Pharma’s Prograf (tacrolimus), GlaxoSmithKline’s (GSK - Analyst Report) Arixtra (fondaparinux) and Bristol-Myers Squibb’s (BMY - Analyst Report) and Sanofi’s (SNY - Analyst Report) Plavix (clopidogrel). Revenues were also boosted by products from the Shreveport facility and the ramp-up in the antibiotics portfolio.

Our Recommendation

We currently have an Outperform recommendation on Dr. Reddy’s, which carries a Zacks #1 Rank (short term ‘Strong Buy’ rating). We are pleased with Dr. Reddy’s geographic reach and product depth along with the robust generic product pipeline. We expect the US generics business to continue performing well in the coming quarters. Other generic companies like Mylan and Watson Pharma currently carry a Zacks #2 Rank (short-term ‘Buy’ rating).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVEST TECH- ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%